0
Signin
countryflagCA

888-969-2592

RY 139.89 0.8943% TD 76.9 1.2242% SHOP 86.16 -18.5248% CNR 172.89 0.5818% ENB 51.15 1.1269% CP 112.14 0.5199% BMO 127.56 0.9816% TRI 229.43 0.1528% CNQ 105.96 1.0105% BN 60.44 0.683% ATD 75.02 0.4015% CSU 3820.47 1.7341% BNS 65.64 1.4685% CM 66.73 1.3364% SU 53.67 0.4304% TRP 52.0 1.069% NGT 57.07 0.3693% WCN 227.19 0.0528% MFC 33.6 0.9919% BCE 46.16 0.5445%

Quest PharmaTech Inc

Healthcare CA QPT

0.03CAD
0.01(50.00%)

Last update at 2024-05-08T13:30:00Z

Day Range

0.030.03
LowHigh

52 Week Range

0.040.11
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-01-31 2022-01-31 2021-01-31 2020-01-31 2019-01-31
Type yearly yearly yearly yearly yearly
Date 2023-01-31 2022-01-31 2021-01-31 2020-01-31 2019-01-31
Income before tax -7.33232M -85.03857M 190.06M -13.25447M -8.64132M
Minority interest - - 0.00000M -1.16071M 5.93M
Net income -7.33232M -85.03857M 190.06M -6.18354M -4.39266M
Selling general administrative 0.50M 0.62M 0.86M 2.37M 2.78M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 0.01M 0.04M 0.04M 0.04M 0.00751M
Ebit -0.83422M -0.79057M -1.07035M -13.63461M -9.04190M
Ebitda -7.29783M -84.98695M 190.11M -13.19795M -8.62939M
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income -0.83422M -0.79057M -1.07035M -13.63461M -9.04190M
Other operating expenses - - - - -
Interest expense 0.02M 0.01M 0.00777M 0.01M 0.00442M
Tax provision - - - - -
Interest income - 0.00000M 0.00183M 0.05M 0.16M
Net interest income -0.02100M -0.01306M -0.00594M 0.03M 0.15M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - -
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 0.83M 0.79M 1.07M 13.63M 9.04M
Cost of revenue - - - - -
Total other income expense net -6.47710M -84.23494M 191.14M 0.35M 0.25M
Discontinued operations - - - -0.02287M -0.03390M
Net income from continuing ops -7.33232M -85.03857M 190.06M -13.25447M -8.64132M
Net income applicable to common shares -7.33232M -85.03857M 190.06M -6.18354M -4.39266M
Preferred stock and other adjustments - - - - -
Breakdown 2023-01-31 2022-01-31 2021-01-31 2020-01-31 2019-01-31
Type yearly yearly yearly yearly yearly
Date 2023-01-31 2022-01-31 2021-01-31 2020-01-31 2019-01-31
Total assets 84.36M 91.03M 175.61M 4.45M 5.81M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - - - - -
Total liab 1.11M 0.62M 0.39M 20.95M 10.14M
Total stockholder equity 83.25M 90.41M 175.22M -15.33568M -10.26743M
Deferred long term liab - - - 1.45M 1.45M
Other current liab - - - 12.35M 9.64M
Common stock 30.74M 30.62M 30.62M 30.57M 30.53M
Capital stock 30.74M 30.62M 30.62M 30.57M 30.53M
Retained earnings 41.49M 48.78M 133.81M -57.09539M -50.90591M
Other liab - - - - -
Good will - - - - -
Other assets 0.01M 0.01M 0.01M 1.46M 1.46M
Cash 0.37M 0.26M 0.20M 2.15M 0.35M
Cash and equivalents - - - - -
Total current liabilities 1.11M 0.62M 0.38M 20.86M 10.14M
Current deferred revenue - - - - -
Net debt 0.63M 0.24M 0.05M 0.49M -
Short term debt - - - - -
Short long term debt 1.00M 0.50M 0.25M 2.65M -
Short long term debt total - - - - -
Other stockholder equity -0.11449M -0.05033M - 0.84M 1.19M
Property plant equipment 0.00297M 0.02M 0.06M 0.10M 0.02M
Total current assets 0.62M 0.29M 0.28M 2.89M 4.30M
Long term investments 83.72M 90.71M 175.27M 0.00000M 0.03M
Net tangible assets 83.25M 90.41M 175.22M -15.33568M -10.26743M
Short term investments - - 0.00000M 0.30M 3.11M
Net receivables 0.22M 0.00032M 0.03M 0.01M 0.01M
Long term debt - - - - -
Inventory - - - - 0.00000M
Accounts payable 0.11M 0.11M 0.09M 5.86M 0.51M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - 1.51M
Deferred long term asset charges - - - - -
Non current assets total 83.74M 90.74M 175.33M 1.56M 1.51M
Capital lease obligations 0.00000M 0.01M 0.05M 0.09M -
Long term debt total - - - - -
Breakdown 2023-01-31 2022-01-31 2021-01-31 2020-01-31 2019-01-31
Type yearly yearly yearly yearly yearly
Date 2023-01-31 2022-01-31 2021-01-31 2020-01-31 2019-01-31
Investments -0.01400M -0.01400M 0.30M 2.81M 8.26M
Change to liabilities 0.00000M 0.02M -0.00148M 5.35M -0.42348M
Total cashflows from investing activities -0.01400M -0.01400M 0.26M 2.78M 8.26M
Net borrowings 0.50M 0.25M 0.25M 2.65M 2.65M
Total cash from financing activities 0.68M 0.25M 0.30M 5.40M -1.42354M
Change to operating activities -0.22523M 0.03M -0.02894M 0.40M -0.24452M
Net income -7.33232M -85.03857M 190.06M -6.18354M -4.39266M
Change in cash 0.11M 0.07M -1.95407M 1.81M -0.06914M
Begin period cash flow 0.26M 0.20M 2.15M 0.35M 0.42M
End period cash flow 0.37M 0.26M 0.20M 2.15M 0.35M
Total cash from operating activities -0.55468M -0.17078M -2.51503M -6.37629M -6.90771M
Issuance of capital stock 0.09M 0.00000M - 2.66M 0.03M
Depreciation 0.01M 0.04M 0.04M 0.04M 0.00751M
Other cashflows from investing activities -0.01400M -0.01400M -0.03804M -0.03585M -0.03585M
Dividends paid - - - - -
Change to inventory - - - 0.00000M 0.00036M
Change to account receivables - 0.03M -0.02180M 0.00337M 0.00874M
Sale purchase of stock - - - - -
Other cashflows from financing activities - - - 2.66M -1.45354M
Change to netincome 6.99M 84.75M -192.56658M -5.98749M -1.86366M
Capital expenditures 0.00000M 0.00000M 0.04M 0.00000M 0.00163M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.22523M 0.08M -0.05222M 5.75M -0.65889M
Stock based compensation 0.15M 0.27M 0.45M 1.43M -
Other non cash items - - -13.54250M -0.34903M -0.26704M
Free cash flow -0.55468M -0.17078M -2.55307M -6.37629M -6.90934M

Fundamentals

  • Previous Close 0.02
  • Market Cap6.77M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-1.17714M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.12

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
QPT
Quest PharmaTech Inc		 0.01 50.00% 0.03 - - 515.97 0.10 -0.345
NGEN
NervGen Pharma Corp		 0.08 3.96% 2.10 - - - 29.48 -6.9477
ARCH
Arch Biopartners Inc		 0.02 1.19% 1.70 - - 37.82 - 53.05 -28.1027
MIR
MedMira Inc		 0.005 5.56% 0.10 - - 170.46 - 189.94 -48.7372
TTI
Thiogenesis Therapeutics Corp.		 - -% 0.70 - - - 11.86 -163.0787

Reports Covered

Stock Research & News

View All

Profile

Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.

Quest PharmaTech Inc

8123 Roper Road NW, Edmonton, AB, Canada, T6E 6S4

Key Executives

Name Title Year Born
Dr. Ragupathy Madiyalakan Ph.D. CEO & Director NA
Mr. Pierre Vermette Chief Financial Officer NA
Mr. Roger Andrews Head of Investor Relations & Corp. Communications NA
Mr. Douglas C. Bachman VP of Corp. Devel. 1954
Mr. Thomas Woo VP of Product Devel. NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).